FDA granted Rare Pediatric Disease designation for THIO in pediatric-type diffuse high-grade gliomas.
HHS Secretary Robert Kennedy Jr. asserted that under his leadership, FDA will “end the war” against alternative medicine.
FDA grants Rare Pediatric Disease designation for THIO in pediatric high-grade gliomas
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Thyme Care expanded its survivorship program and comprehensive cancer care services with the appointment of two experienced medical directors: Asma Dilawari as medical director of oncology care, who will lead the company’s survivorship program expansion, and Nelia Jain as medical director of palliative care, who will scale Thyme Care’s virtual palliative care offering, called Enhanced Supportive Care.
FDA has approved Ibtrozi (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Booth 10025 became an unlikely crowd magnet at the exhibit hall at the annual meeting of the American Society of Clinical Oncology that ended earlier this week.
Mehmet Oz, Robert F. Kennedy Jr., Marty Makary, Jayanta Bhattacharya, and Vinayak Prasad at an FDA Roundtable on Cell and Gene Therapy, June 5.Speaking at an FDA Roundtable on Cell and Gene Therapy, FDA Commissioner Marty Makary questioned the construct of “levels of evidence” as artificial and dogmatic, saying that n-of-1 “stories” can drive regulatory decisions.
FDA rolled out a generative artificial intelligence tool designed to help employees across the agency “work more efficiently.”
